大隐静脉

dà yǐn jìnɡ mài
  • great saphenous vein
大隐静脉大隐静脉
  1. 方法大隐静脉曲张患者283例,其中单纯大隐静脉曲张278例,同时伴有轻度胭静脉返流5例。

    Methods Two hundred eighty-three patients with varicosis of great saphenous vein , in which 278 cases were great saphenous vein varicosis only and 5 cases were coexist great saphenous vein varicosis with mild blood reflex of popliteal veins .

  2. 导管引导下硬化剂注射治疗大隐静脉曲张的护理

    Nursing of Catheter-guided Foam Sclerotherapy Treatment for Great Saphenous Vein

  3. 目的:研究在29名正常及32名曲张的大隐静脉壁上雌激素(E)受体和黄体酮(P)受体的表达,探讨雌激素和黄体酮受体表达与静脉曲张发生的关系;

    AIM The presence of estrogen and progesterone receptors was investigated in the walls of normal and varicose vein .

  4. 目的观察使用Symmetry主动脉吻合器时对大隐静脉移植物内皮有无损伤。

    Purpose To evaluate the injury with Symmetry aortic connector to saphenous venous endothelial cells .

  5. 化合物HL-328对离体家兔大隐静脉的作用

    Effect of Compound HL 328 on Isolated Rabbit Saphenous Vein

  6. 目的①观察曲张大隐静脉(varicosegreatsaphenous,VGS)管壁的光镜结构和超微结构的改变;

    Objective ① To observe the microstructural and ultrastructural changes of the varicose great saphenous vein .

  7. 大隐静脉曲张光凝治疗后血清IL-2和sIL-2R的测定

    Changes of Serum IL-2 and sIL-2R Levels after Intravenous Photo-coagulation in Patients with Varicose Greater Saphenous Vein

  8. 大隐静脉曲张血管内光凝治疗后LPO,SOD,GSH-Px的变化

    Changes of Blood Levels of LPO , SOD and GSH-Px after Endovenous Laser Treatment of Varicose Greater Saphenous Vein

  9. 血管内光凝治疗大隐静脉曲张围手术期血浆ET-1和NO的水平

    Changes of Levels of Plasma ET-1 and NO After Intravenous Photocoagulation of the Varicosis of Greater Saphenous Vein

  10. Symmetry主动脉吻合器对大隐静脉移植物的损伤新型可调式免缝合人造主动脉移植物的研究

    Injury with Symmetry Aortic Connector to Saphenous Venous Endothelial Cells in Coronary Artery Bypass Grafting Preliminary experimental study on a novel adjustable sutureless aortic prosthesis

  11. 结果:大隐静脉曲张患者LPO水平较正常水平高,SOD、GSH-Px水平较正常水平低。

    Results The levels of LPO were higher and levels of SOD 、 GSH-Px lower in the patients than those in the controls .

  12. 目的:测定血管内激光光凝治疗大隐静脉曲张围手术期血浆内皮素-1(ET-1)和一氧化氮(NO)的水平。

    Objective To determine the changes of levels of plasma endothelin-1 ( ET-1 ) and nitric oxide ( NO ) after intravenous photocoagulation of the varicosis of the greater saphenous vein .

  13. 目的:大隐静脉(SV)是CABG术中常用的血管材料之一,然而SVG再狭窄仍是临床亟待解决的难题。

    OBJECTIVES : Saphenous vein ( SV ) is one of the most common used vascular materials for CABG , but restenosis of these vein grafts remains a clinical problem .

  14. 1在4块皮瓣蒂部远端的大隐静脉中滴注标记了99mTc的红细胞;

    The erythrocytes marked with 99m Tc were droped into great saphenous veins in the distal place to the pedicles in 4 flaps ;

  15. 10年以上为2.56%。39例患者共移植血管101支,其中左乳内动脉桥(LIMA)36支,大隐静脉桥54支,桡动脉桥11支。

    Totally there were 101 bypass grafts including 36 left internal mammary arteries ( LIMA ), 54 great saphenous vein grafts and 11 radial artery grafts .

  16. 结论对离体培养的人大隐静脉平滑肌细胞磷酸化ERK进行阻断后,平滑肌细胞的增殖受抑,凋亡增加,细胞由合成型向收缩型转变。

    Conclusion After the activated ERK was inhibited , the degree of cellular proliferation was decreased , the degree of apoptosis increased and the phenotype changed from synthetic to contractile .

  17. 目的:测定大隐静脉曲张血管内光凝治疗前后血清中白细胞介素-2(sIL-2R)及其可溶性受体(sIL-2R)的变化。

    Objective To determine the changes of serum interleukin 2 ( IL-2 ) and soluble interleukin 2 receptor ( sIL-2R ) levels in patients with varicose greater saphenous vein after intravenous photocoagulation .

  18. 移植大隐静脉长度13~45cm。

    The length of transplantation of the great saphenons vein was from 13 cm to 45 cm .

  19. 方法应用TriVex系统对55例(70条肢体)下肢大隐静脉曲张患者施行了TIPP。

    Methods Fifty-five patients with lower extremity varicose vein were treated by TIPP .

  20. 采用大隐静脉(SVs)及左内乳动脉(LIMAs)作为移植物材料。

    The long saphenous veins ( SVs ) and left internal mammary arteries ( LIMAs ) were harvested as grafts .

  21. 目的介绍冠状动脉旁路移植术(CABG)游离大隐静脉(GSV)无腿部切口感染的经验。

    Objective To introduce experience of harvesting great saphenous vein ( GSV ) and surgical techniques to avoid infectious complication in coronary artery bypass grafting ( CABG ) .

  22. PCCS联合大隐静脉高位结扎+抽剥术是治疗下肢浅静脉曲张比较理想的手术方法。

    PCCS , combined with greater saphenous vein ligation and stripping , is an ideal method for varicosis of lower extremities .

  23. 结果由近及远,隐神经-大隐静脉营养血管来自隐动脉3~5支,外径0.7±0.4mm;

    Results The nutritional vessels of sural nerve-great saphenous vein originated from : the saphenous artery 3-5 branches with a diameter of 0.7 ± 0.4 mm ;

  24. 目的评价以透光旋切系统(TriVexTM)治疗下肢大隐静脉曲张,即透照下动力静脉切除术(TIPP)的疗效。

    Objective To assess the effect of transilluminating rotating resecting system in treatment of varicose great saphenous vein ( transilluminated powered phlebectomy , TIPP ) .

  25. 同时56例大隐静脉曲张患者行传统的大隐静脉高位结扎、分段剥脱治疗,同样在治疗后第1,3,7和14d检测血浆内ET-1和NO水平。

    Another fifty-six patients with varicosis of greater saphenous vein were treated with the traditional high ligation and stripping method . The levels of ET-1 and NO on 1st , 3rd , 7th and 14th day postoperatively were also determined too .

  26. 结论RFO闭合大隐静脉具有创伤小、恢复快、腿部少留瘢痕等优点,是一种可部分替代传统大隐静脉高位结扎剥脱术的有效方法。

    Conclusions RFO effectively obliterates the whole length of the great saphenous vein and is of less trauma , faster recovery , and less scars .

  27. 目的利用基因芯片技术分析原发性下肢深静脉瓣膜功能不全(PDVI)所致大隐静脉曲张的基因表达谱和差异基因。

    Objective To analyze gene expression profiles in varicose of the great saphenous vein resulting from primary deep vein valve insufficiency ( PDVI ) by cDNA microarray .

  28. 目的评价腔内激光治疗大隐静脉曲张(ELVT)的近期疗效。

    Objective To evaluate the short term results of endovascular laser for the treatment ( ELVT ) of great saphenous varicosity .

  29. 目的:探讨常温下尼可地尔(nicorandil,NCR)和罂粟碱对大隐静脉血管桥血管内皮超极化因子(endothelium-derivedhyperpolarizingfactor,ED-HF)介导血管舒张功能的影响。

    AIM : To explore the protective effect of nicorandil ( NCR ) and papaverine on saphenous vein graft ( SVG ) endothelium derived hyperpolarizing factor ( EDHF ) mediated vasodilatation under normal temperature . METHODS : The organ chamber technique was used .

  30. 目的筛选原发性下肢深静脉瓣膜功能不全(PDVI)患者中大隐静脉曲张的致病相关基因。

    Objective To screen and identify the genes related to the occurrence and development of varicose great saphenous vein in the patients with primary deep vein valve insufficiency ( PDVI ) .